Summit Therapeutics Inc.

Summit Therapeutics’ updated HARMONi analysis strengthens the ivonescimab survival trend in Western and Asian lung cancer patients ahead of the FDA decision. Representative image.

Pharma & Biotech

Summit Therapeutics nears FDA decision with stronger ivonescimab survival signal

by Pallavi Madhiraju
July 22, 2026
0 Comments

Ivonescimab’s updated HARMONi survival trend strengthens before the FDA’s November decision, but key statistical details remain undisclosed.

Read More

Representative image: A clinician reviews lung cancer imaging as ivonescimab survival data from the HARMONi-6 study raise fresh questions about the future of first-line squamous non-small cell lung cancer treatment.

Pharma & Biotech

Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?

by Pallavi Madhiraju
June 1, 2026
0 Comments

Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.

Read More